Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand

HIV Medicine

Volumn 10, Issue 2, 2009, Pages 72-78

  Lee, B ^a   Aurpibul, L ^b   Sirisanthana, V ^c   Mangklabruks, A ^b   Sirisanthana, T ^b   Puthanakit, Thanyawee ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Antiretroviral therapy; C peptide; Homeostasis model assessment (HOMA); Insulin; Insulin resistance; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT; C PEPTIDE; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; GLUCOSE; INSULIN; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; UNCLASSIFIED DRUG;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPODYSTROPHY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; THAILAND;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; MALE; THAILAND;

EID: 68949102262     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00653.x     Document Type: Article

References (48)

1. Palella FJ Jr, Delaney K, Moorman A et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
2. Puthanakit T, Oberdorfer A, Akarathum N et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's national access to antiretroviral program. Clin Infect Dis 2005; 41: 100-107.
3. Puthanakit T, Aurpibul L, Oberdorfer P et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 44: 599-604.
4. Puthanakit T, Aurpibul L, Oberdorfer P et al. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J 2007; 26: 953-956.
5. Walli R, Herfort O, Michl G et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12: F167-F173.
6. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
7. Behrens G, Dejam A, Schmidt H et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63-F70.
8. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm D, Cooper D. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999; 353: 2093-2099.
9. Behrens G, Meyer-Olson D, Stoll M, Schmidt R. Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 2003; 17 (Suppl. 1): S149-S154.
10. Goran M, Gower B. Longitudinal study on pubertal insulin resistance. Diabetes 2001; 50: 2444-2450.
11. Moran A, Jacobs DR Jr, Steinberger J et al. Insulin resistance during puberty: Results from clamp studies in 357 children. Diabetes 1999; 48: 2039-2044.
12. Rondanelli M, Caselli D, Trotti R et al. Endocrine pancreatic dysfunction in HIV-infected children: Association with growth alterations. J Infect Dis 2004; 190: 908-912.
13. Chantry C, Frederick M, Meyer WA III et al. Endocrine abnormalities and impaired growth in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2007; 26: 53-60.
14. Jaquet D, Levine M, Ortega-Rodriguez E et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000; 14: 2123-2128.
15. Amaya R, Kozinetz C, McMeans A, Schwarzwald H, Kline M. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21: 405-410.
16. Bitnun A, Sochett E, Babyn P et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and -naïve HIV-infected children. AIDS 2003; 17: 1319-1327.
17. Beregszaszi M, Dollfus C, Levine M et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005; 40: 161-168.
18. Bitnun A, Sochett E, Dick P et al. Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naïve human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2005; 90: 168-174.
19. Hartman K, Verweel G, de Groot R, Hartwig N. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25: 427-431.
20. Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J. Prevalence of lipodystrophy in HIV-infected children: A cross-sectional study. Eur J Pediatr 2007; 166: 13-21.
21. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
22. Yeckel C, Weiss R, Dziura J et al. Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metab 2004; 89: 1096-1101.
23. Keskin M, Kurtoglu S, Kendirci M, Atabek M, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005; 115: e500-e503.
24. Atabek M, Pirgon O. Assessment of insulin sensitivity from measurements in fasting state and during an oral glucose tolerance test in obese children. J Pediatr Endocrinol 2007; 20: 187-195.
25. Conwell L, Trost S, Brown W, Batch J. Indexes of insulin resistance and secretion in obese children and adolescents: A validation study. Diabetes Care 2004; 27: 314-319.
26. Uwaifo G, Fallon E, Chin J, Elberg J, Parikh S, Yanovski J. Indices of insulin action, disposal, and secretion derived from fasting samples and clamps in normal glucose-tolerant black and white children. Diabetes Care 2002; 25: 2081-2087.
27. Wallace T, Levy J, Matthews D. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
28. The European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004; 18: 1443-1451.
29. Sanchez Torres A, Munoz Muniz R, Madero R, Borque C, Garcia-Miguel M, De Jose Gomez M. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 2005; 164: 271-276.
30. Aurpibul L, Puthanakit T, Lee B, Mangklabruks A, Sirisanthana T, Sirisanthana V. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir Ther 2007; 12: 1247-1254.
31. Carr A, Emery S, Law M, Puls R, Lundgren J, Powderly W. An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 2003; 361: 726-735.
32. Kosmiski L, Kuritzkes D, Lichtenstein K et al. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 2001; 15: 1993-2000.
33. Lichtenstein K. Redefining lipodystrophy syndrome: Risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39: 395-400.
34. Sinha R, Fisch G, Teague B et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002; 346: 802-810.
35. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43 (RR-12): 1-10.
36. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection Supp III: Adverse drug effects. Bethesda, MD: US Department of Health and Human Services 2006, 30 pp.
37. Rosso R, Parodi A, d'Annunzio G et al. Evaluation of insulin resistance in a cohort of HIV-infected youth. Eur J Endocrinol 2007; 157: 655-659.
38. Leonard E, McComsey G. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival. Infect Dis Clin North Am 2005; 19: 713-729.
39. Haugaard S, Andersen O, Volund A et al. Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Clin Endocrinol (Ord) 2005; 62: 354-361.
40. Mallon P, Wand H, Law M, Miller J, Cooper D, Carr A. Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia. J Acquir Immune Defic Syndr 2005; 38: 156-162.
41. Melvin A, Lennon S, Mohan K, Purnell J. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retroviruses 2001; 17: 1117-1123.
42. McComsey G, Bhumbra N, Ma J, Rathore M, Alvarez A. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: Results of the First Pediatric Switch Study. Pediatrics 2003; 111: E275-e281.
43. Guillén S, Ramos J, Resino R et al. Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J 2007; 26: 334-338.
44. Verweel G, van Rossum A, Hartwig N, Wolfs T, Scherpbier H, de Groot R. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics 2002; 109: E25.
45. Martins P, Sawaya A. Evidence for impaired insulin production and higher sensitivity in stunted children living in slums. Br J Nutr 2006; 95: 996-1001.
46. Martins V, Martins P, Neves J, Sawaya A. Children recovered from malnutrition exhibit normal insulin production and sensitivity. Br J Nutr 2008; 99: 297-302.
47. Palmer J, Fleming G, Greenbaum C et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: Report of an ADA Workshop, 21-22 October 2001. Diabetes 2004; 53: 250-264.
48. World Health Organization. Antiretroviral therapy for HIV infections in adults and adolescents in resource-limited settings: Recommendations for a public health approach. 2006 rev. Geneva, Switzerland: WHO, Department of HIV/AIDS, 2006, 128 pp.